Joe McCracken, D.V.M.

Dr. McCracken has served as Savara’s lead independent director since December 2019 and as a member of the company’s Board of Directors since October 2013. Dr. McCracken currently advises biopharmaceutical companies on the design and implementation of corporate strategy and business development initiatives. He also serves on the Board of Directors of Modalis Therapeutics Corporation, as well as the Board of Directors of the privately held company Eos Therapies. Dr. McCracken previously served on the Board of Directors of Lumos Pharma, Inc., Kindred Biosciences, Inc., and Alkahest, Inc. until their acquisitions in 2024, 2021, and 2020, respectively. He also served on the Board of Directors for Neuropore Therapies until February of 2024 and Regimmune Inc. until May of 2023. Previously, Dr. McCracken was Vice President and Global Head of Business Development and Licensing for Roche Pharma, a research-focused healthcare company, where he was responsible for global in-licensing and out-licensing activities. Prior to that he served as General Manager, Roche Pharma Japan and Asia Regional Head, Roche Partnering. Prior to Roche Pharma, Dr. McCracken held the position of Vice President, Business Development at Genentech, and previously held similar positions at Aventis Pharma and Rhone-Poulenc Rorer. Dr. McCracken holds a B.S. in Microbiology, a M.S. in Pharmacology, and a D.V.M. from The Ohio State University.